Τετάρτη 9 Νοεμβρίου 2022

Obesity-related SNPs and weight gain following first-line antiretroviral therapy

alexandrossfakianakis shared this article with you from Inoreader

cid_ogimage.png

Abstract
Background
We studied the association of obesity-related SNPs (OR-SNPs) with weight gain after antiretroviral therapy (ART) in people with HIV (PWH).
Methods
Participants were ART-naïve PWH from the Spanish HIV Research Cohort who started ART from 2014 onwards and had blood/DNA deposited in the cohort Biobank. The primary outcome was change in weight at 96 weeks after starting ART. We genotyped 14 OR-SNPs from a meta-analysis of GWAS body mass index (B MI) loci. Changes over time in weight and BMI were studied using adjusted linear mixed models (A-LMM).
Results
A total of 1,021 PWH were included. The mean weight gain over 96 weeks was 2.90 (95% CI: 2.54–3.26) Kg. Factors associated with higher weight gain were female sex, birth in Sub-Saharan Africa, prior AIDS, CD4+ < 200 cells/uL, HIV-RNA > 100,000 copies/mL, negative HCV serology, and use of tenofovir alafenamide. A significant association was found between ZC3H4 rs3810291 GG genotype and BCDIN3D/FAIM2 rs7138803 GG genotypes polymorphisms and weight and BMI increase. The estimated adjusted mean (SE) of weight gains were 4.26 (0.56) Kg in ZC3H4 rs3810291 GG carriers and 2.66 (0.19) Kg in AA/AG carriers (P = 0.007). Likewise, the estimated means (SE) weight gain at 96 weeks were 3.35 (0.29) Kg in BCDIN3D/FAIM2 rs7138803 GG carriers and 2.51 (0.24) Kg in AG/AA carriers (P = 0.020).
Conclusions
Genetic factors may play a role in weight gain after ART initiation. Further work is needed to replicate our findings and understand how the identified SNPs lead to higher weight gain in this context.
View on Web

Maternal Antibody Response and Transplacental Transfer Following SARS-CoV-2 Infection or Vaccination in Pregnancy

alexandrossfakianakis shared this article with you from Inoreader

cid_ogimage.png

Abstract
Background
Pregnant persons are at increased risk of severe COVID-19 and adverse obstetric outcomes. Understanding maternal antibody response, duration, and transplacental transfer after SARS-CoV-2 infection and COVID-19 vaccination is important to inform public health recommendations.
Methods
This prospective observational cohort study included 351 pregnant people who had SARS-CoV-2 infection or COVID-19 vaccination during pregnancy. IgG and IgM to SAR S-CoV-2 S1 receptor binding domain were measured in maternal and cord blood. Antibody levels and transplacental transfer ratios were compared across 1) disease severity for those with SARS-CoV-2 infection and 2) infection versus vaccination.
Results
There were 252 individuals with SARS-CoV-2 infection and 99 who received COVID-19 vaccination during pregnancy. Birthing people with more severe SARS-CoV-2 infection had higher maternal and cord blood IgG levels (p = 0.0001, p = 0.0001). Median IgG transfer ratio was 0.87-1.2. Maternal and cord blood IgG were higher after vaccination than infection (p = 0.001, p = 0.001). Transfer ratio was higher after 90 days in the vaccinated group (p < 0.001). Modeling showed higher amplitude and half-life of maternal IgG following vaccination (p < 0.0001). There were no significant differences by fetal sex.
Conclusions
COVID-19 vaccination in pregnancy leads to higher and longer lasting maternal IgG le vels, higher cord blood IgG, and higher transfer ratio after 90 days compared to SARS-CoV-2 infection. Greater infection severity leads to higher maternal and cord blood antibodies. Maternal IgG decreases over time following both vaccination and infection, reinforcing the importance of vaccination, even after infection, and vaccine boosters for pregnant patients.
View on Web

Radiomics‐based machine learning for the diagnosis of lymph node metastases in patients with head and neck cancer: Systematic review

alexandrossfakianakis shared this article with you from Inoreader

Abstract

Machine learning (ML) is increasingly used to detect lymph node (LN) metastases in head and neck (H&N) carcinoma. We systematically reviewed the literature on radiomic-based ML for the detection of pathological LNs in H&N cancer. A systematic review was conducted in PubMed, EMBASE, and the Cochrane Library. Baseline study characteristics and methodological quality items (modeling, performance evaluation, clinical utility, and transparency items) were extracted and evaluated. The qualitative synthesis is presented using descriptive statistics. Seven studies were included in this study. Overall, the methodological quality items were generally favorable for modeling (57% of studies). The studies were mostly unsuccessful in terms of transparency (85.7%), evaluation of clinical utility (71.3%), and assessment of generalizability employing independent or external validation (72.5%). ML may be able to predict LN metastases in H&N cancer. Further studies are warranted to impro ve the generalizability assessment, clinical utility evaluation, and transparency items.

View on Web

Clinical trials on the pharmacological treatment of long COVID: a systematic review

alexandrossfakianakis shared this article with you from Inoreader

Abstract

Background

The post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC), also known as post-acute coronavirus disease 19 (COVID-19) or the long COVID syndrome (long COVID) is an emerging public health concern. A substantial proportion of individuals may remain symptomatic months after initial recovery. An updated review of published and ongoing trials focusing on managing long COVID will help identify gaps and address the unmet needs of patients suffering from this potentially debilitating syndrome.

Methods

A comprehensive literature search was conducted on the international databases and clinical trial registries from inception to 31 July 2022.

Results

This review included 6 published trials and 54 trial registration records. There is significant heterogeneity in the characterization of long COVID and ascertainment of primary outcomes. Most of the trials are focused on individual symptoms of long COVI D or isolated organ dysfunction, classified according to cardiovascular, respiratory and functional capacity, neurological and psychological, fatigue, and olfactory dysfunction. Most of the interventions are related to the mechanisms causing the individual symptoms. Although the 6 published trials showed significant improvement in the symptoms or organ dysfunction studied, these initial studies lack internal and external validity limiting the generalizability.

Conclusions

This review provides an update of the pharmacological agents that could be used to treat long COVID. Further standardization of the diagnostic criteria, inclusion of participants with concomitant chronic cardiometabolic diseases and standardization of outcomes will be essential in future clinical trials.

This article is protected by copyright. All rights reserved.

View on Web

Comprehensive analysis of HHV‐6 and HHV‐7‐related gene signature in prognosis and response to temozolomide of glioma

alexandrossfakianakis shared this article with you from Inoreader

Abstract

Background

Human herpesvirus (HHV)-6 and HHV-7 have been detected in central nervous system and glioma tissue, while their exact role in glioma remains uncertain.

Methods

Omics profiles and clinical information were downloaded from public databases, including TCGA cohort for training set and the CGGA cohorts for validation sets. Differentially expressed genes between HHV-6 and HHV-7 infected or non-infected glioma patients were screened for establishing the HHV-6 and HHV-7 infection (HI) model through Lasso regression analysis. Bioinformatics methods were used to analyze the correlation between HI scores and prognosis, metastasis in glioma patients. Predictable efficacy of HI in temozolomide-resistance and HI-related genetic signatures were also explored.

Results

The HI model was constructed as: Risk score = (0.014709*DIRAS3) + (0.029787*TEX26) + (0.223492*FBXO39) + (0.074951*MYBL1) + (0.060202*HILS1). The 5 gene signature showed good perfor mance in predicting survival time for glioma patients, while higher HI score is correlated with malignant features. Moreover, DNA mismatch repair genes were augmented in glioma patients with higher HI score as well as non-response to temozolomide treatment, which was in parallel with the transcriptomic result of temozolomide-resistant glioma cell.

Conclusions

Targeting the five gene signature is beneficial for prognosis of glioma patients, especially in glioma patients underwent temozolomide treatment.

This article is protected by copyright. All rights reserved.

View on Web

Ocular survival after intra‐arterial chemotherapy for retinoblastoma improves with accrual of experience and programmatic evolution

alexandrossfakianakis shared this article with you from Inoreader

Abstract

Background

Intra-arterial chemotherapy (IAC) for the treatment of intraocular retinoblastoma has gained recognition as a method to improve ocular salvage; however, there is a paucity of evidence supporting treatment factors prognosticating ocular survival.

Methods

All patients with retinoblastoma treated with IAC at a single institution between December 2008 and December 2019 were evaluated. Patient demographics, tumor classification, prior treatments, procedural data, other non-IAC therapies, adverse reactions, procedural complications, ocular outcomes, and overall survival were assessed via retrospective chart review. Factors suggestive of increased ocular survival were identified via univariate and multivariate analyses. The impact of accrued treatment experience was evaluated by grouping eyes by the respective year, IAC treatment was initiated.

Results

Forty-nine eyes of 43 patients were treated for retinoblastoma with IAC (256 total procedures). At least grade 3 neutropenia was observed following 19% of IAC procedures. The risk of neutropenia was not statistically different between single or multidrug IAC. Comparing those who received balloon-assisted intra-arterial chemotherapy (bIAC) in more than two-thirds of cycles to those who did not, the risk of arterial access site complications was not statistically different. Multivariate analysis revealed a significantly lower risk of enucleation associated with treatment era in years (hazard ratio [HR] = 0.52–1.00, p < .05) and laser therapies (HR = 0.02–0.60, p < .05).

Conclusions

Ocular survival rates in patients treated with IAC for retinoblastoma at our institution have increased over time. Accrued treatment experience and programmatic changes have likely contributed. Larger, prospective series may lead to a better understanding of factors that consistently contribute to better ocular salvage.

View on Web

RANDOMISED CLINICAL TRIAL TO ASSESS THE IMPACT OF ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE (CPC) TO REDUCE SALIVARY SARS‐CoV‐2 VIRAL LOAD

alexandrossfakianakis shared this article with you from Inoreader

Abstract

Background

Aerosols released from the oral cavity help spread the SARS-CoV-2 virus. The use of a mouthwash formulated with an antiviral agent could reduce the viral load in saliva, helping to lower the spread of the virus.

Aim

The aim of this study was to assess the efficacy of a mouthwash with 0.07% cetylpyridinium chloride to reduce the viral load in saliva of COVID-19 patients.

Material and Methods

In this multi-centre, single-blind, randomised, parallel group clinical trial, 80 COVID-19 patients were enrolled and randomised to two groups, test (N=40) and placebo (N=40). Saliva samples were collected at baseline and 2 hours after rinsing. The samples were analysed by RT-qPCR and an ELISA test specific for the nucleocapsid (N) protein of SARS-CoV-2.

Results

By means of RT-qPCR, no significant differences were observed between the placebo group and the test group. However, 2 hours after a single rinse N protein concentration in saliva was significantly higher in the test group, indicating an increase in lysed virus.

Conclusions

The use of 0.07% CPC mouthwash induced a significant increase in N protein detection in the saliva of COVID-19 patients. Lysis of the virus in the mouth could help reduce the transmission of SARS-CoV-2. However, more studies are required to prove this.

This article is protected by copyright. All rights reserved.

View on Web

A 53‐year‐old woman with a rapidly progressive, non‐enhancing left frontotemporal lesion

alexandrossfakianakis shared this article with you from Inoreader

This website stores data such as cookies to enable essential site functionality, as well as marketing, personalization, and analytics. You may change your settings at any time or accept the default settings. Privacy Policy
Manage Preferences
Accept All
Skip to Article Content
Skip to Article Information
Working off-campus? Learn about our remote access options

Wiley Online Library
Search
Search within
This Journal
Search term
Search

Login / Register
Brain Pathology
Brain Pathology
CASE IMAGE
Open Access
A 53-year-old woman with a rapidly progressive, non-enhancing left frontotemporal lesion
Michael L. Miller,Daniel W. Griepp,Yu Sun,Sean Tamir,Rebecca Straus Farber,Marc L. Otten,Osama Al-Dalahmah
First published: 08 November 2022 https://doi.org/10.1111/bpa.13125
Michael L. Miller and Daniel W. Griepp contributed equally to this study.
SECTIONSPDFPDFTOOLS SHARE
Abstract
Fifty-three-year-old woman presented with chronic, episodic headache.

Description unavailable
1 CLINICAL HISTORY AND IMAGING
A 53-year-old woman presented with chronic, episodic headache. The patient's headache was first noted several years prior to presentation and would occur for weeks to months, then remit for several weeks to months. More recently, the severity of the headache worsened which prompted a referral to neurology. The patient's past medical history included bilateral knee arthralgia and swelling about 6 years prior to presentation, which since resolved. While the symptoms raised the possibility of Lyme disease or rheumatoid arthritis (RA), neither diagnosis was confirmed. Given the patient's intractable headache, magnetic resonance imaging (MRI) was performed which revealed a non-enhancing left frontal white matter lesion (Figure 1A). On evaluation by neurosurgery, observation was initially recommended with the possibility of open biopsy. At follow-up, despite resolution of the patient's presenting symptom of headache, the patient began to show signs of subjective neurocognitive impairment s, including word-finding difficulty, poor performance playing chess, and fear of driving. Repeat imaging 3 months since presentation revealed progression of the lesion (Figure 1B) with expansion into the temporal lobe (not shown). Given the relatively rapid radiographic progression, the lesion was biopsied with concern for a neoplastic process (Box 1).

Details are in the caption following the image
FIGURE 1
Open in figure viewer
PowerPoint
Brain magnetic resonance imaging. Axial plane FLAIR sequences at initial presentation (A) and at follow up 3–4 months later (B) revealed relatively rapid progression of the left frontal lobe.
BOX 1. Slide scan
Access the whole slide scan at https://isn-slidearchive.org/?col=ISN&fol=Archive&file=BPA-21-12-302.svs

2 FINDINGS
Hematoxylin and eosin (H&E)-stained sections revealed gliotic brain. Mixed chronic- and focally acute-appearing inflammatory infiltrates composed primarily of histiocytes and multinucleated giant cells, with scant lymphocytes and occasional eosinophils, involved most cortical vessels (Figure 2A–C). Transmural disruption and focal necrosis were also identified (Figure 2A), as were scattered well-formed granulomas. Cortical and leptomeningeal vessels appeared thickened and occasionally produced a double-barreled appearance. Focally exuberant perivascular hemosiderin deposits were identified. Within the vessel walls, deposition of amorphous, congophilic material was identified that appeared green-red birefringent under polarized light (Figure 2D,E). Immunohistochemistry with beta-amyloid revealed intense circumferential staining in the leptomeningeal and cortical blood vessels (Figure 2F).

Details are in the caption following the image
FIGURE 2
Open in figure viewer
PowerPoint
Histology of brain biopsy. Gliotic brain parenchyma with focal fibrinous exudate of vessels (A) and angiocentric inflammation composed of monocytes, lymphocytes, and prominent giant cells (B). (C) Giant cells were highlighted with CD68 immunostain. (D) Congophilic material within vascular walls, which appeared apple-green when viewed under polarized light (inset). (E and F) Intense, circumferential accumulation of beta-amyloid around intraparenchymal vessel, including vessels with prominent transmural inflammation (for all, scale bar = 50 μm)
3 FINAL DIAGNOSIS
Amyloid beta-related angiitis (ABRA).

4 DISCUSSION
A defining feature of ABRAis the presence of cerebral amyloid angiopathy (CAA) in association with vasculitis [1]. Given prognostic and predictive differences of ABRA when compared to CNS vasculitis in the absence of CAA and CAA in the absence of vasculitis, accurate distinction is clinically meaningful [2]. For instance, in contrast to ABRA, primary CNS vasculitis without CAA generally results in a less favorable outcome [2]. While CAA is primarily the result of imbalanced amyloid production and clearance, ABRA is thought to occur when beta-amyloid vascular deposits are recognized as foreign antigens [1]. Although ABRA generally occurs earlier in life compared to CAA, most studies describe presentation of ABRA in the sixth or seventh decades of life [1, 3]. Predisposing factors to the development of ABRA are not clearly defined, although it is associated with preexisting autoimmune processes, prior radiation treatment, and ApoE4 genotype. It is notable that the present patient was r elatively young and had a possible history of rheumatoid arthritis.

The inflammatory process of ABRA results in the destruction of vessels. Previously reported cases of ABRA were typically characterized by severe leptomeningeal and parenchymal amyloid angiopathy, along with chronic inflammation within the leptomeninges and in and around vessel walls [3]. Granulomatous inflammatory infiltrates and large multinucleated macrophages are also characteristic findings [1, 3]. Extensive fibrinoid necrosis of vessels may be identified [3]. Features characteristic of CAA may also be observed, such as hemosiderin-laden macrophages suggestive of prior hemorrhage [3]. Many of these histopathological features were appreciated in the present case.

Diagnosis of ABRA is difficult given the generally non-specific clinical presentation and broad radiographic diagnosis. While the signs of CAA are more likely to manifest as spontaneous lobar intracerebral hematoma or progressive dementia, the presenting signs of ABRA may include seizure, mental status change, headache, or newly recognized focal neurological deficits. Radiographic changes are also nonspecific, but typically include asymmetric subcortical white matter lesions, evidence of microhemorrhages, and leptomeningeal enhancement. The present patient's clinical presentation was non-specific and consisted of headache that progressed to word-finding difficulty. The radiographic presentation showed a non-enhancing white matter lesion as well as several punctate areas of susceptibility outside of the lesion. Thus overall, prior to biopsy, there was a concern for malignancy although a diverse differential including inflammatory processes was considered.

Definitive diagnosis of ABRA is rendered through microscopic examination of a targeted brain biopsy. The most successful treatments reported include immunosuppression with prednisone and/or cyclophosphamide, although other immunosuppressive agents have been successful [1, 3]. With treatment, approximately three quarters of patients recover to some degree while approximately one quarter develops relapses [1]. While in our case, the patient's young age and the rapid radiologic progression of the lesion prompted a biopsy—which was diagnostic—it is important to remember that when ABRA/CAA is clinically suspected, the diagnosis can be made without surgery when imaging is supportive.

AUTHOR CONTRIBUTIONS
Michael L. Miller, Daniel W. Griepp and Osama Al-Dalahmah wrote the original draft. Yu Sun, Sean Tamir, Rebecca Straus Farber and Marc L. Otten reviewed and edited the draft.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ETHICS STATEMENT
All data related to this case are deidentified.

Open Research
REFERENCES

Early View

Online Version of Record before inclusion in an issue

e13125

Figures
References
Related
Information
Recommended
Subcortical hematoma caused by cerebral amyloid angiopathy: Does the first evidence of hemorrhage occur in the subarachnoid space?

Shigeki Takeda, Kazunori Yamazaki, Teruo Miyakawa, Kiyoshi Onda, Kaoru Hinokuma, Fusahiro Ikuta, Hiroyuki Arai
Neuropathology
Cerebral amyloid angiopathy: An overview

Masahito Yamada
Neuropathology
Human cerebral amyloidosis

Blas Frangione
Drug Development Research
Absence of the cystatin C amyloid in the cerebral amyloid angiopathy, senile plaque, and extra-CNS amyloid deposits of aged Japanese

M. Yamada, H. Tsukagoshi, Y. Wada, E. Otomo, M. Hayakawa, L. Thorsteinsson, O. Jensson
Acta Neurologica Scandinavica
SORL1 gene mutation and octapeptide repeat insertion in PRNP gene in a case presenting with rapidly progressive dementia and cerebral amyloid angiopathy

Federica Cencini, Marcella Catania, Giuseppe Di Fede, Giacomina Rossi, Katia Khouri Chalouhi, Chiara Manfredi, Giorgio Giaccone, Pietro Tiraboschi, Anna Bersano, Elisabetta Groppo, Chiara Rosci, Lucia Tancredi, Laura Campiglio, Amedeo De Grado, Alberto Priori, Emma Scelzo
European Journal of Neurology
Download PDF
Back
Additional links
About Wiley Online Library
Privacy Policy
Terms of Use
About Cookies
Manage Cookies
Accessibility
Wiley Research DE&I Statement and Publishing Policies
Developing World Access
Help & Support
Contact Us
Training and Support
DMCA & Reporting Piracy
Opportunities
Subscription Agents
Advertisers & Corporate Partners
Connect with Wiley
The Wiley Network
Wiley Press Room
Copyright © 1999-2022 John Wiley & Sons, Inc. All rights reservedWiley Home Page

A 53-year-old woman with a rapidly progressive, non-enhancing left frontotemporal lesion

Fifty-three-year-old woman presented with chronic, episodic headache.


View on Web

Uprighting a Mesially Tilted Molar Using Customized Titanium Healing Abutment of an Adjacent Osseointegrated Implant

alexandrossfakianakis shared this article with you from Inoreader

Abstract

This case report evaluates the use of a customized healing abutment of a dental implant to upright a mesially tilted molar using elastic separating rings. The external surface of the healing abutment was roughened by air particle abrasion, and a flowable composite was applied as a collar around it. The size of the resin collar was increased several times during the molar uprighting treatment by replacing the elastic ring. The uprighting procedure was evaluated after 2 months using radiographic and clinical evaluations. After treatment, the mesiodistal space above the implant was increased from 6 mm to 9 mm as follows: 2 mm by uprighting the second molar and 1 mm by mesial shifting the second premolar, and then a screw-retained zirconia crown was placed to restore the implant. The healing abutment of the implant can be modified by adding a resin collar and used as orthodontic anchorage for uprighting the adjacent tilted molar to facilitate the prosthetic procedure. Neither special instruments nor an orthodontic background are required for this minor tooth movement.

This article is protected by copyright. All rights reserved

View on Web

Αρχειοθήκη ιστολογίου